Skip to main content

Market Overview

Alpine Is A Buy Ahead Of Clinical Trials, Wedbush Says In Positive Initiation

Alpine Is A Buy Ahead Of Clinical Trials, Wedbush Says In Positive Initiation

Wedbush analysts see an attractive entry point for Alpine Immune Sciences Inc. (NASDAQ: ALPN), as the biotech's initial candidates will enter the clinic over the next year.

The Analyst

Robert Driscoll of Wedbush initiated coverage on Apline with an Outperform rating and $13 price target.

The Thesis

Alpine’s “directed evolution” approach to multifunctional protein-based therapeutics could modulate immune synapse better than conventional immunotherapeutics for treatment of cancer and autoimmune or inflammatory diseases, Driscoll said in a note. (See the analyst's track record here.) 

The company's variable immunoglobin domain platform uses directed evolution to create novel therapeutics and could have a broad utility across therapeutic modalities, the analyst said.

Alpine's ALPN-101 is expected to enter the clinic in the fourth quarter, Driscoll said. 

“ALPN-101 has demonstrated compelling preclinical activity in multiple models of inflammation and autoimmune disease." 

Another key asset is the ALPN-202 immuno-oncology program, which could prove to be a strong competitor, the analyst said. 

“We see the targeting of multiple pathways with a single molecule as providing significant advantages over other I-O combination approaches in development, including selectivity, convenience and cost.”

Price Action

Alpine shares were rallying nearly 10 percent to $9.69 at the time of publication Friday afternoon. 

Related Links:

Jounce Therapeutics Stock Slides On Disappointing Data, Wells Fargo Downgrades

Zoetis To Buy Abaxis In $2B Deal

Latest Ratings for ALPN

Dec 2020HC Wainwright & Co.Initiates Coverage OnBuy
Aug 2020Cowen & Co.Initiates Coverage OnOutperform
Aug 2020Piper SandlerMaintainsOverweight

View More Analyst Ratings for ALPN
View the Latest Analyst Ratings


Related Articles (ALPN)

View Comments and Join the Discussion!

Posted-In: Robert Driscoll WedbushAnalyst Color Biotech Price Target Initiation Analyst Ratings General Best of Benzinga

Latest Ratings

LBCredit SuisseMaintains36.0
TRGPCredit SuisseMaintains40.0
SNOWCredit SuisseMaintains275.0
DARCredit SuisseMaintains95.0
CLRMKM PartnersDowngrades26.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at